Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
NCT ID: NCT00742066
Last Updated: 2011-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
32 participants
INTERVENTIONAL
2008-03-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.
NCT00180024
L-Arginine Metabolism in Essential Hypertension
NCT00137124
Emerging Biomarkers in Hypertension
NCT02064218
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
NCT05529147
Study of Inherited Changes of Receptors Located on Blood Vessels
NCT00001741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I
Irbesartan
Irbesartan
Single dose 600mg orally
II
Felodipine
Felodipine
single dose 10mg Felodipine ER
III
Placebo
Placebo
Single dose tablet orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Irbesartan
Single dose 600mg orally
Felodipine
single dose 10mg Felodipine ER
Placebo
Single dose tablet orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. 18-60 years
2. Caucasian
3. untreated hypertension \>140/90mmHg.
normotensive subjects:
1. 18-60 years
2. Caucasian
3. Blood pressure \<140/90 mmHg.
Exclusion Criteria
2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
4. Smoking
5. Alcohol use \>4U/day
6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
7. Pregnancy
8. Wearing contact lenses
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital Maastricht
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
CDA Stehouwer, Prof.
Role: STUDY_CHAIR
Univeristy Hospital Maastricht
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Maastricht
Maastricht, P.O. Box 5800, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEC 07-2-115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.